Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PembroMetaRT in metastatic head and neck squamous cell carcinoma
NCT04747054Phase 3Recruiting
- Sponsor
- Unicancer
- Start
- Dec 2021
- Primary completion
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Unicancer. Started Dec 2021; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04747054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04747054.